Xenon Pharmaceuticals to Report Phase 3 Epilepsy Trial Results for Azetukalner
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
Xenon Pharmaceuticals Inc. will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on Monday, March 9, 2026. The company will present results during a conference call and webcast scheduled for 8:00 a.m. ET.
Azetukalner is described as a novel, potent KV7 potassium channel opener currently in Phase 3 clinical trials for epilepsy treatment, as well as for major depressive disorder and bipolar depression. The drug represents Xenon's lead molecule in development.
The company will host a live webcast accessible through the Investors section of its website, with a replay to be available following the event. Participants can join via toll-free dial-in at (800) 715-9871 or international line at (646) 307-1963, using conference ID 7885306.
About 30 per cent of focal onset seizure patients continue to experience refractory seizures, underscoring demand for once-daily treatments with limited drug interactions. The company released very strong Phase II data several years ago, and investors have been waiting a few years for the Phase III readout. Xenon and azetukalner have produced some of the best seizure-reduction data seen so far.
The $3.5 billion market cap company maintains a strong balance sheet, holding more cash than debt with a current ratio of approximately 13. Price targets range from $47 to $66.
Xenon Pharmaceuticals expects to report topline data from the Phase 3 X-TOLE2 study for azetukalner in March 2026, with plans for a New Drug Application submission later that year.
Beyond azetukalner, the company is advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. The company maintains offices in Vancouver, British Columbia, and Boston, Massachusetts.